This page compiles U.S. Securities and Exchange Commission (SEC) filings for ParkerVision, Inc. (PRKR), a Florida corporation focused on radio-frequency (RF) technologies for advanced wireless communication systems. Through its periodic and current reports, ParkerVision provides detailed information on its operations, financial condition, litigation posture, and capital-raising activities.
Investors can use ParkerVision’s annual reports on Form 10-K and quarterly reports on Form 10-Q to review its RF technology and licensing focus, operating expenses, net losses, contingent payment obligations, and cash flows. These filings also include risk factor discussions that the company references in its press releases, covering topics such as outcomes of patent litigation, interpretations of patent law and claim scope, decisions by the Patent Trial and Appeal Board (PTAB), and market conditions affecting financing.
Current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe registered direct offerings of common stock under ParkerVision’s effective shelf registration statement on Form S-3, including sales to accredited investors and to a director. These filings outline subscription agreements, offering prices, aggregate purchase amounts, and legal opinions regarding the issuance of securities. Other 8-Ks furnish earnings press releases that summarize quarterly and year-to-date financial results and provide context for changes in operating expenses and contingent payment obligations.
Through this filings page, users can access ParkerVision’s real-time updates as they are filed with EDGAR, including 10-K, 10-Q, and 8-K reports, as well as registration statements and prospectus supplements related to its shelf registration. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections such as litigation disclosures, capital structure changes, and risk factors, and make it easier to interpret complex legal and financial language without replacing the full primary documents.
ParkerVision, Inc. registers 9,387,500 shares of Common Stock for resale by selling shareholders as set forth in the prospectus supplement dated May 7, 2026.
The prospectus supplement states the company will not receive proceeds from resales by the selling shareholders; if the 200,000 Options are exercised for cash, the company would receive up to $42,620 in gross proceeds to be used for general working capital purposes. As of May 1, 2026, 147,767,649 shares of common stock were outstanding.
ParkerVision, Inc. registers the resale of up to 16,638,353 shares of Common Stock issuable upon conversion of convertible promissory notes with a fixed conversion price of $0.13 per share. This supplement attaches the company's Form 10-Q filed May 7, 2026.
The 10-Q shows cash and cash equivalents of $3.4 million, an accumulated deficit of $457.2 million, and a secured contingent payment obligation measured at fair value of $40.1 million. Shares outstanding were 147,767,649 as of May 1, 2026. The 10-Q also discloses substantial doubt about the company’s ability to continue as a going concern for the next twelve months.
ParkerVision, Inc. files a prospectus supplement registering 1,578,946 shares of common stock for resale by a selling stockholder. The registration covers 1,052,631 shares and 526,315 shares underlying warrants issued under a December 14, 2021 agreement. The company will not receive proceeds from the resale; however, if the 526,315 Warrants are exercised for cash, the company would receive up to $526,315 in gross proceeds to be used for general working capital, including litigation expenses. Shares outstanding were 147,767,649 as of May 1, 2026. This supplement updates the prospectus with the company’s Form 10-Q for the quarter ended March 31, 2026.
ParkerVision, Inc. filed a Prospectus Supplement dated May 7, 2026 registering the resale of 13,342,953 shares of Common Stock under a prior prospectus. The supplement states the company will not receive proceeds from sales by the selling stockholders; however, if underlying warrants are exercised for cash, the company would receive up to $2,833,756 in gross proceeds.
The supplement attaches the company’s Form 10-Q for the quarter ended March 31, 2026, which shows cash of $3.4 million, a net loss for the quarter of $1.553 million, and total secured contingent payment obligations measured at fair value of $40.144 million. Shares outstanding were 147,767,649 as of May 1, 2026. The filing reiterates substantial litigation-driven operations, contingent payment obligations tied to patent proceeds, and management’s statement of substantial doubt about going concern for the next year.
ParkerVision, Inc. files a Prospectus Supplement registering 5,871,584 shares of common stock for resale by selling stockholders. The supplement attaches ParkerVision’s Form 10-Q for the quarter ended March 31, 2026 and states the company will not receive proceeds from these resales.
The Form 10-Q shows $3.4 million in cash, a net loss of $1.553 million for the three months ended March 31, 2026, secured contingent payment obligations of $40.144 million, and 147,767,649 shares outstanding as of May 1, 2026. The filing discloses substantial doubt about the company’s ability to continue as a going concern for one year.
ParkerVision, Inc. filed a Prospectus Supplement dated May 7, 2026 registering 16,809,295 shares of Common Stock for resale by selling stockholders. The registration covers listed conversion shares, private-offering issuances, shares issued for services/repayments, and up to warrants exercisable for up to 5,200,000 shares.
The company will not receive proceeds from resales by selling stockholders; however, it would receive up to $3,900,000 if the Aspire and Tailwinds warrants are exercised for cash. The supplement incorporates ParkerVision’s Form 10-Q for the quarter ended March 31, 2026, which shows cash of $3.4M, an accumulated deficit of $457.2M, a secured contingent payment obligation measured at $40.144M, and shares outstanding of 147,767,649 as of May 1, 2026. The 10-Q also discloses substantial doubt about the company’s ability to continue as a going concern for one year.
ParkerVision, Inc. files a Prospectus Supplement registering 18,014,164 shares of common stock for resale by selling stockholders, as described in the Prospectus Supplement dated May 7, 2026. The registration covers (i) up to 5,457,583 shares issuable upon conversion of Tranche 1 Notes at a fixed conversion price of $0.10 per share, (ii) up to 10,131,581 shares issuable upon conversion of Tranche 2 Notes at a fixed conversion price of $0.08 per share, (iii) up to 625,000 shares issued for services under the Fisher Consulting Agreement, and (iv) up to 1,800,000 shares issuable upon exercise of a five-year Park Consulting Warrant with an exercise price of $0.10 per share. The company will not receive proceeds from sales by the selling stockholders; however, if the Park Consulting Warrant is exercised for cash, ParkerVision would receive up to $180,000 in gross proceeds.
Context: shares outstanding were 147,767,649 as of May 1, 2026. The supplement attaches the registrant's Form 10-Q for the quarter ended March 31, 2026.
ParkerVision filed a Prospectus Supplement registering 17,189,660 shares of common stock for resale by selling stockholders under previously filed registration statements. The supplement attaches the company's Form 10-Q for the quarter ended March 31, 2026 and notes that the company will not receive proceeds from selling stockholders' resales. The company may receive proceeds only if certain warrants are exercised (including up to $700,000 from the 2016 Warrant and potential proceeds related to the Aspire PIPE arrangements); any proceeds received are expected to be used to fund patent enforcement actions and for working capital.
ParkerVision, Inc. files a prospectus supplement updating its April 19, 2019 prospectus to register the resale of 12,800,000 shares of Common Stock, consisting of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from resale by selling stockholders; to the extent the warrant is exercised for cash, the company would receive up to $800,000, which it expects to use for patent enforcement actions and general corporate purposes.
The supplement incorporates ParkerVision's Form 10-Q for the quarter ended March 31, 2026, which shows cash and cash equivalents of $3.4 million, a net loss of $1.553 million for the quarter, and a secured contingent payment obligation carried at fair value of $40.144 million. Shares outstanding were 147,767,649 as of May 1, 2026. The company discloses substantial doubt about its ability to continue as a going concern for one year absent licensing proceeds, conversions/extensions of convertible notes, or additional financing.
ParkerVision, Inc. reported another weak quarter as it continues to rely on patent litigation and licensing. The company generated no licensing revenue in Q1 2026 and posted a net loss of about $1.6 million, narrower than the $3.8 million loss a year earlier, mainly due to lower legal and professional fees and a smaller increase in contingent payment obligations.
Cash and cash equivalents were about $3.4 million at March 31, 2026, with working capital of roughly $1.7 million. Total assets were only $4.5 million against total liabilities of about $50.0 million, leaving shareholders’ deficit near $45.5 million. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern over the next year.
ParkerVision’s capital structure remains highly leveraged to future litigation outcomes. The fair value of its secured contingent payment obligation to litigation funder Brickell Key Investments was $40.1 million, with an underlying note carrying roughly $69.4 million of face value plus accrued interest. Unsecured contingent payment obligations totaled about $6.3 million. In March 2026, the company exchanged around $0.7 million of convertible notes and interest for approximately 3.3 million unregistered common shares, realizing a small loss on extinguishment.